ICH S2(R1): the standard genotoxicity battery for pharmaceuticals

No single test can see every way a molecule might damage the genome. Gene mutations, structural chromosome breaks, whole-chromosome loss — each needs a different lens. That is why pharmaceutical genotoxicity assessment is built not around one assay but around a battery, and why that battery is harmonised worldwide by ICH S2(R1).

“Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use” is the guideline that tells developers which tests to run, in what combination, and how to interpret the results. This article is the map: what the battery covers, the two options available, and how the individual assays fit together.

What the battery is designed to catch

Genotoxic damage comes in three broad forms, and a credible battery must cover all of them:

• Gene mutations — point mutations and small changes in the DNA sequence;
• Structural chromosomal damage (clastogenicity) — breaks and rearrangements;
• Numerical chromosomal damage (aneugenicity) — gain or loss of whole chromosomes.

No single assay reads all three, so ICH S2(R1) combines complementary methods across bacterial, mammalian and in vivo systems.

The two standard battery options

Option 1 — the in-vitro-anchored battery

• A bacterial reverse mutation test (Ames, OECD 471) for gene mutation;
• An in vitro test for chromosomal damage — the in vitro micronucleus test (OECD 487) or chromosomal aberration test (OECD 473) — or an in vitro mouse lymphoma TK assay (OECD 490);
• An in vivo genotoxicity test, typically the rodent bone-marrow micronucleus test.

Option 2 — the in-vivo-weighted battery

• A bacterial reverse mutation test (Ames);
• An in vivo assessment covering two tissues — usually a micronucleus endpoint plus a second, such as the comet assay (OECD 489).

Both options are considered equally acceptable; the choice depends on the compound, the development stage and the overall data strategy.

Interpreting the results

A positive result does not automatically end a programme. ICH S2(R1) promotes a weight-of-evidence approach: assessing biological relevance, reproducibility, dose–response and mechanism, and using follow-up testing to determine whether an in vitro signal is meaningful in vivo. This measured interpretation is as important as the tests themselves.

Build your battery with GenEvolutioN

GenEvolutioN designs and runs complete ICH S2(R1) genotoxicity batteries under GLP — from the Ames test through in vitro chromosomal-damage and gene-mutation assays to in vivo endpoints — and helps you interpret and defend the results.

Explore the individual assays: the Ames test, the micronucleus test, and the genotoxicity fundamentals — or talk to our team.